Company Tiziana Life Sciences PLC London S.E.

Equities

GB00B28XMY25

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote London S.E. Other stock markets
- ^GBX	-

05-10	Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-25	Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	CI

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Managers	Title	Age	Since
Gabriele Cerrone CEO	Chief Executive Officer	52	10/02/98
Keeren Shah DFI	Director of Finance/CFO	47	-
Vaseem Palejwala CTO	Chief Tech/Sci/R&D Officer	-	31/12/16
Matthew Davis COO	Chief Operating Officer	-	30/06/22
Paul Spencer IRC	Investor Relations Contact	-	30/11/22
William Clementi PRN	Corporate Officer/Principal	-	31/08/23

Members of the board	Title	Age	Since
John Brancaccio BRD	Director/Board Member	76	30/06/20
Willy Simon BRD	Director/Board Member	72	31/10/15
Gabriele Cerrone CEO	Chief Executive Officer	52	10/02/98

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	194,612,289	63,373,729 ( 32.56 %)	0	32.56 %

Name	Equities	%	Valuation
Gabriele Cerrone 38.03 %	38,890,635	38.03 %	33 M p
Geode Capital Management LLC 0.2110 %	215,825	0.2110 %	181 509 p
HSBC Bank Plc 0.1606 %	164,226	0.1606 %	138 114 p
Morgan Stanley Capital Services LLC 0.1214 %	124,131	0.1214 %	104 394 p
Ausdal Financial Partners, Inc. 0.0545 %	55,700	0.0545 %	46 844 p
EWA LLC 0.0541 %	55,300	0.0541 %	46 507 p
Zhang Financial LLC 0.0509 %	52,060	0.0509 %	43 782 p
UBS Securities LLC 0.0305 %	31,244	0.0305 %	26 276 p
Bank of America, NA (Charlotte, North Carolina) 0.0264 %	27,011	0.0264 %	22 716 p
Barclays Bank Plc 0.0171 %	17,500	0.0171 %	14 718 p

Name	Equities	%	Valuation
ACCUSTEM SCIENCES, INC. 11.80%	1,337,970	11.80%	445,544 $

Tiziana Life Sciences Ltd.

14/15 Conduit Street

W1S 2XJ, London

http://www.tizianalifesciences.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research